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CMV Infection Exacerbates IBD
Active CMV infection in the colon exacerbates inflamma-
tory bowel disease (IBD). To determine whether latent
CMV infection affects the development and/or severity of
IBD, Onyeagocha et al (Am J Pathol 2009, 175: 2034-
2042) examined mice with latent murine CMV (MCMV)
infection, ie, mice infected at low viral levels only detect-
able by PCR. Latent CMV infection did not induce IBD in
either wild-type mice or a colitis-prone mouse model, but
it did exacerbate the severity of colitis induced by an-
other mechanism. MCMV infection resulted in increased
numbers of intestinal lymphocytes and heightened anti-
body responses to commensal microbial antigens, which
are associated with IBD severity. Therefore, modulation
of mucosal immunity by latent CMV may contribute to the
pathogenesis of IBD.
Eosinophils in Allergy and Asthma
Asthma and allergic disease are associated with an im-
proper Th2 immune response. Although eosinophils have
long been considered the terminal effectors in allergic
and asthmatic Th2 immune responses, they are also
capable of modulating the adaptive immune response by
interacting with T cells to promote Th2 polarization. More-
over, eosinophils in the thymus may contribute to immune
development; therefore, Tulic et al (Am J Pathol 2009,
175: 2043-2052) examined the ontogeny of thymic eosin-
ophils in children. They observed an age-dependent de-
crease in the number of eosinophils in the thymus, sug-
gesting an early role of eosinophils in Th2 bias. These
eosinophils expressed indoleamine 2,3-dioxygenase,
which depletes tryptophan, resulting in activation of
kynurenines and subsequent apoptosis in Th1 but not
Th2 cells. Taken together, these results suggest an early
immunomodulatory role for eosinophils, which may play a
pivotal role in Th2 immune development.
GAGs in Bone Pathology
Mucopolysaccharidoses (MPSs) are a group of lysosomal
storage diseases that result in decreased breakdown
and thus increased accumulation of glycosaminoglycans
(GAGs) in various tissues. GAGs have been shown to
inhibit the collagenolytic activity of cathepsin K in oste-
oclasts; the resultant collagen accumulation leads to in-
sufficient space for bone formation and consequent bone
pathology. As MPS patients have severe deficiencies in
bone growth and development, Wilson et al (Am J Pathol
2009, 175: 2053-2062) hypothesized that cathepsin K
inhibition may contribute to bone pathology in MPS pa-
tients. They found that GAG expression colocalized with
cathepsin K in the growth plates of a mouse model of
MPS type I and that higher levels of cartilage accumu-
lated in bone growth plates of MPS I mice than in their
wild-type counterparts. In addition, cathepsin K-medi-
ated collagen degradation was significantly reduced in
osteoclasts from MPS I mice. These data suggest that
increased GAG expression in MPS inhibits cathepsin K
function, resulting in collagen accumulation in the bone
growth plate and subsequent bone pathology.
CpG DNA Therapy for Alzheimer’s Disease
Accumulation of soluble oligomeric amyloid  (oA) pep-
tide leads to neurological dysfunction in Alzheimer’s dis-
ease patients. Microglia cluster around senile A plaques
in Alzheimer’s disease patients; however, the role of mi-
croglia in oA toxicity remains unclear. Doi et al (Am J
Pathol 2009, 175: 2121-2132) discovered that microglial
activation with unmethylated CpG DNA, a ligand for Toll-
like receptor 9, prevented oA toxicity and enhanced
A peptide clearance in culture. Furthermore, intracere-
broventricular injection of class B and C CpG DNA miti-
gated both cognitive impairment and learning defects in
a mouse model of Alzheimer’s disease. CpG DNA may
therefore be a therapeutic candidate for treatment of
Alzheimer’s disease.
Vitronectin Receptor Inhibits Ovarian Cancer
Progression
Vitronectin receptor (v3-integrin) expression plays a
key role in tumor progression in breast cancer and mel-
anoma as well as in tumor angiogenesis in endothelial
cells. Kaur et al (Am J Pathol 2009, 175: 2184-2196)
therefore examined the function of v3-integrin in ovar-
ian cancer. In contrast to other tumor models, ovarian
cancer cells that overexpressed v3-integrin showed
impaired invasion, protease expression, and colony for-
mation in vitro; proliferated at a slower rate; and produced
fewer metastatic nodules in vivo than control cells. Con-
versely, inhibiting 3-integrin increased ovarian cancer
cell invasion and proliferation, whereas high 3-integrin
expression significantly improved ovarian cancer patient
prognosis. v3-Integrin is therefore not an appropriate
therapeutic target for ovarian cancer.
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